Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives. (BioWorld Today)

Johnson & Johnson went a long way toward strengthening its oncology pipeline, agreeing to buy Cougar Biotechnology Inc. in a deal worth just under $1 billion. (BioWorld Today)

For cash-starved biotechs that have not yet found a parter or buyer, and are not in the running for any grant money or government contracts, there may be few options for survival in today's economy.

Celgene Corp. will pay GlobeImmune Inc. $40 million up-front to gain access to all of the company's cancer drug programs. (BioWorld Today)